Rocco Serrao, MD

Rocco Serrao, MD, Dermatologist, Mason, Ohio; roflumilast clinical trial investigator

Articles by Rocco Serrao, MD

Lawrence Eichenfield, MD, Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics

Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis

ByLawrence Eichenfield, MD,Rocco Serrao, MD

October 7th 2025

A pair of roflumilast clinical trial investigators react to the FDA approval of the 0.05% formulation to treat atopic dermatitis in children aged 2 to 5 years.

Latest Updated Articles

Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis
Published: October 7th 2025 | Updated:

Rocco Serrao, MD

Articles by Rocco Serrao, MD

Lawrence Eichenfield, MD; and Rocco Serrao, MD, react to roflumilast approval for pediatric atopic dermatitis

Latest Updated Articles

Trending on Contemporary Pediatrics

Olivia Kim-McManus, MD, discusses genetic testing, therapy in pediatric neurology

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years

Long-term outcomes of lentiviral gene therapy for ADA-deficient severe combined immunodeficiency